CNTX Stock — Context Therapeutics Inc.: Metrics

Market overview

2 metrics

Share price

$0.36

Market cap

$33.32M

Price action

19 metrics

Price change (1W)

-5.8%

Price change (30D)

-28.2%

Price change (3M)

-79.3%

Price change (6M)

-88.4%

Price change (YTD)

-75.4%

Price change (1Y)

-56.3%

Trailing year

Price change (5Y)

—

52-week high

$3.36

52-week low

$0.36

Change from 52-week high

-89.2%

Change from 52-week low

+0.0%

Annualized volatility

106.6%

Beta

0.3

RSI (14D)

28.3

Price vs SMA 50

-33.4%

Price vs SMA 200

-77.9%

Avg volume (3M)

2.87M

Relative volume

0.3

Average dollar volume

$1.71M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

91.88M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

0.9

reciprocal yield 114.5%

FCF yield

-102.1%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-137.9%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-06-15

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$48.73M

Net income (TTM)

−$45.96M

Trailing 12 months

Diluted EPS (TTM)

$-0.48

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-51.00

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

0.0%

Year over year · fewer shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-120.4%

Return on assets

-99.6%

Debt / equity

—

Current ratio

5.8

EBITDA (TTM)

—

Free cash flow (TTM)

−$34.03M

Quick ratio

5.8

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$42.99M

Latest balance sheet

Cash & equivalents

$42.99M

Total assets

$46.13M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$33.97M

Capital expenditures (TTM)

$55,746

R&D (TTM)

$40.11M

SG&A (TTM)

—

Stock compensation (TTM)

$1.59M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

79

13F filer change QoQ

+19

Institutional ownership

68.4%

Short interest

3 metrics

Short interest

6.8%

Latest settlement · 3.1 days to cover

Days to cover

3.1d

Short-squeeze score

52 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

CNTX · Context Therapeutics Inc.

CNTX metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search